GSK announces start of Phase lll study for mepolizumab in patients with Eosinophilic Granulomatosis with Polyangiitis

GlaxoSmithKline (GSK) today announced the start of a Phase III study to evaluate the efficacy and safety of mepolizumab, an investigational IL-5 antagonist.